

Call 10 Two-Stage call

Rules and Procedures

Alessandro Chiodini, Call Coordinator Desmond Barry, Legal and Intellectual Property Officer



Before we start...

- We are recording this session and it will be published on the IHI website.
 We will also publish the presentation slides.
- The call has been launched this morning and all links and details on how to apply are published on the Funding and Tenders Portal and the IHI website.
- Final approved call 10 text already available here.
- If you want to ask a question please use the Q&A function on the right corner of your screen.



Outline



Participation rules



Funding rules



Intellectual property rules



Proposal template and evaluation criteria



Grant Agreement & Consortium Agreement



Call timelines



Points to remember



IHI two-stage calls

Pre-identified industry consortium (including contributing partners if any) align themselves around a real challenge in health care agree to work together (across sectors) and commit resources

New ideas from **Applicant consortium** (research organisations, patient organisations, SMEs, other healthcare stakeholders etc.) are needed to address the challenge

Scale is a key to success and is provided by the leveraging of IHI funding with industry contributions in the **Full consortium** (Public Private Partnership)

Outcomes should be transformative for healthcare and meet end-users needs



IHI two-stage call 10 - topics


Digital label: one source of comprehensive information for medical technology products

Enabling and safeguarding innovation in secondary use of health data in the European Health Data Space (EHDS)

Per- and Poly-fluoroalkyl substance (PFAS) exposure, emissions, and end of life management in the healthcare sector



How does IHI two-stage procedure work •



IHI JU Specific types of Beneficiaries

Two-Stage Calls: Private members and Contributing Partners

Pre-identified - responsible for the 45% in-kind contribution

main drivers of the topic definition

identify their in-kind contributions through expertise and assets

listed in the topic text (overall contribution and not per partner)

not eligible for funding

can not participate with the applicant consortium

Not pre-identified

any other participant that is part of the applicant consortium during the stage 1

not involved in the topic definition

they could join the consortium afterwards (i.e GAP or during the project implementation via amendment)

can be eligible for funding

do not contact the pre-identified industry consortium during the application process





Eligibility:

consortia; to participate; to receive funding.



Basics of Eligibility for IHI JU Actions

IHI JU projects are undertaken by consortia.

Consortia in IHI JU projects are composed of *eligible* 'legal entities' drawn from health research and treatment sectors.

Aspects of Eligibility

- What is a 'legal entity'?
- How to ensure that a consortium is eligible to participate in IHI actions?
- When is a legal entity eligible to participate in IHI JU actions?
- When is a legal entity eligible to receive funding in IHI JU actions?



What is a legal entity?


'legal entity' means a natural person, or a legal person created and recognised as such under Union, national or international law, which has legal personality and the capacity to act in its own name, exercise rights and be subject to obligations, or an entity which does not have legal personality as referred to in point (c) of Article 197(2) of the Financial Regulation; [Horizon Europe Regulation, Article 2]

How to ensure that a consortium is eligible to participate in IHI actions?

- at least one independent legal entity established in an EU Member State, and
- at least two other independent legal entities each established either in a different EU Member State or a Horizon Europe Associated Country*.



MSs, ACs, LMICs, and non-Associated Third Countries



Eligibility to Participate

'Any legal entity, regardless of its place of establishment and including legal entities from non-associated third countries or international organisations, may participate in actions under the Programme...' [Horizon Europe Regulation, Article 22.1]

Eligibility to Receive Funding

In general,* legal entities are entitled to receive funding from IHI JU if they:

- Are established in a Member State of the European Union ('MS'), or;
- Are established in an Associated Country** ('AC'), or;
- Are established in a Low to Middle Income country ('LMIC').

For Two-Stage calls the following legal entities are not eligible to receive funding:

- Legal entities in the pre-identified industry consortium in the topic text;
- Legal Entities with an annual turnover of EUR 500million or more.



^{*} Eligibility for funding is determined by the type of IHI JU call

^{**} Canada (from 2023) and United Kingdom ['UK'] (from 2024) are considered Associated Countries for IHI JU.

Third Countries

Legal entities from non-associated Third Countries do not count towards the above (but these entities are eligible to participate).

Examples of non-associated Third Countries:

- Switzerland*;
- United States of America ('USA').

Exceptional Funding

Legal entities established in non-associated Third Countries may, in exceptional circumstances, receive funding from IHI JU when the legal entity's participation is considered essential (for example, access to particular expertise, data etc.)



Special rules apply for legal entities from certain countries

Ukraine

Given the invasion of Ukraine by Russia and the involvement of Belarus:

 Legal entities established in Russia, Belarus, or in non-government-controlled territories of Ukraine are not eligible to participate in any capacity (beneficiaries, affiliated entities, associated partners, third parties giving in-kind contributions, subcontractors or recipients of financial support to third parties)

Hungary

Council Implementing Decision (EU) 2022/2506 on measures for the protection of the Union budget against breaches of the principles of the rule of law in **Hungary** that took effect on 16 December 2022.

- No European funds are made available, directly or indirectly, to third parties that are public interest trusts established on the basis of the Hungarian Act IX of 2021 or any entity maintained by such a public interest trust. This concerns legal commitments involving Union funding e.g. related to:
 - the purchase of goods, works or services; subcontracting; financial support to third parties;
 equipment renting or leasing; personnel seconded against payment.




Intellectual Property Rights ('IPR') in IHI



Snapshot of key IP concepts for IHI Actions

Background identification



Background: As defined in the MGA (Article 16.1), "Background' means any data, know-how or information — whatever its form or nature (tangible or intangible), including any rights such as intellectual property rights — that is:

- (a) held by the beneficiaries before they acceded to the Agreement and
- (b) needed to implement the action or exploit the results".

Results: any tangible or intangible effect of the action, such as data, know-how or information, whatever its form or nature, whether or not it can be protected, as well as any rights attached to it, including intellectual property rights



Access Rights: define who and when can use Background and Results

IHI Joint Undertaking: Intellectual Property

Points to note on IHI IP*

- IHI IPR rules derived from:
 - Horizon Europe Model Grant Agreement ('MGA') Article 16;
 - supplemented by specific rules identified in HE MGA Annex 5 and;
 - where relevant, the applicable call conditions.
- IHI JU maintains right to object to transfers of ownership of results or to grants of exclusive licences.
- Affordable Access Provisions can, when provided for in the call conditions, introduce additional exploitation obligations for relevant IHI topics;
- Results Ownership List ('ROL') to be submitted at project end as part of final periodic report listing all
 results and ownership of them (including joint ownership structures).
- Emphasis on Exploitation and Open Science:
 - HE MGA integrates Open Science dissemination model;
 - Unexploited project results can be matched with interested parties via the Horizon Results platform.





Proposal template and evaluation criteria



Proposal Template - Part A

 Part A of the proposal is generated by the IT system. It is based on the information entered by the participants through the submission system in the Funding & Tenders Portal.

 The participants can update the information in the submission system at any time before final submission Call: HORIZON-JU-IHI-2025-10-two-stage
(Innovative Health Initiative JU Call 10)

Topic: HORIZON-JU-IHI-2025-10-03-two-stage

Type of action: HORIZON-JU-RIA
(HORIZON JU Research and Innovation Actions)

Type of Model Grant Agreement: HORIZON Action Grant Budget-Based Proposal number: SEP-211119953

Proposal acronym: Test-AC-8-3

Table of contents





Proposal Template - Part B

All templates are available in the submission environment and in IHI Website



Part B of the proposal is the narrative part that includes three sections that each correspond to an evaluation criterion.

Excellence

Impact

Quality and efficiency of the implementation



RIA short proposal is maximum 20 pages.



The proposal should respect the page limit set out in the application form. Excess pages will be automatically made illegible and will not be taken into consideration by the evaluators.



Annex

Annex	Description
Type of Participants (IHI specific annex)	 This annex enables IHI to meet its reporting obligations on the type of participants. Even though this annex will not be part of the evaluation by the independent experts, applicants will not be able to finalise their submission without uploading this Annex in the Submission Tool.

In this section you may upload the technical annex of the proposal (in PDF format only) and any other requested attachments Part B * Upload here Type of Participants * Upload here



Call 10 two-stage - Highlight



Indicative contribution

For each topic, the maximum JU contribution and the estimated industry contributions are set in the call text

2

Plan for Dissemination, Exploitation and Communication Activities (PDECA)

It must be included in second the stage


3

Essential information for clinical studies

For topic(s) involve clinical studies, applicants should submit the annex (admissibility condition) in the second stage



Evaluation flow and thresholds





Evaluation flow and thresholds

- Minimum of 3 independent experts
- Each proposal evaluated 'as it is', not as 'what could be'
- Sub-criteria listed in evaluation form

Criteria	Threshold
Excellence	3/5
Impact	3/5
Implementation	3/5
TOTAL	10/15



Evaluation – Tips

Excellence:

- Address all the objectives of the topic text (unless written otherwise). You should not pick and choose or you will be penalized.
- Clearly describe how your methodology has incorporated knowledge from various stakeholders. This is NOT about the consortium composition but about the knowledge build into the methodology

Impact

 Please provide meaningful and MEASURABLE estimates when it comes to your project's contribution to impacts. We often see unrealistic impacts with no justification.

Implementation

- Prepare clear graphs, do not list deliverables at this stage, focus on the overall structure of your project, your WPs and their overall objectives.
- Reflect and leave some space to describe how your consortium will fit with the industry consortium: read the topic text and what the industry is bringing to the project and show you have taken this into consideration, and you are aware that you are not on your own.







Grant Agreement & Consortium Agreement



CONSORTIUM AGREEMENT

The Agreement (the *Agreement) is effective (EARS).

BETPECEN: [PRET PARTY NAME] (the *Younder'), with its address booted at:

[POUR COMPLETE ACCRESS)

AND: [SECOND PARTY NAME] (the *Younder'), with its address booted at:

[POUR COMPLETE ACCRESS)

INCOMPLETE ACCRESS)

INCOMPLETE ACCRESS (the *Younder'), with its address bounded at:

[POUR COMPLETE ACCRESS)

INCOMPLETE ACCRESS (the *Younder'), with its address bounded at:

[POUR COMPLETE ACCRESS)

INCOMPLETE ACCRESS (the *Younder'), with its address bounded at:

[POUR COMPLETE ACCRESS (the *Younder'), with its address bounded at:

[POUR COMPLETE ACCRESS (the *Younder'), with its address and work to be obtained by the Agreement its address and work to be obtained and its Pour Payment and of the Accusate Agreement in the Text accress and work to be obtained and access and work to be obtained and access and ac



IHI Joint Undertaking: Grant & Consortium Agreements

Grant Agreement ('GA')

- The new Horizon Europe Model Grant Agreement 'HE MGA' includes 44 articles, as well as specific Annexes.
- IHI JU follows HE MGA with IHI JU specificities reflected in Annex 5.
- It is e-signed between IHI JU and Coordinator only. Other beneficiaries e-sign Accession Forms.

Consortium Agreement ('CA')

- Contractual arrangement between all participants to set out their rights and obligations, especially governance, liability and IPR.
- IHI JU is not a party/signatory to the CA.
- The terms of the CA must with the HE MGA (no conflict/contradictions).
- To be adapted to the specific needs of each IHI JU action.
- To be fully agreed before the signature of the IHI JU action's grant agreement.
- Templates are available online:
 - Private Members' prepared template for IHI JU actions (here);
 - Development of a Simplified Consortium Agreement ('DESCA') template.



Timelines



Call 10 - two-stage — Indicative timelines





Points to remember



Points to remember

Horizon Europe Rules for participation apply to IHI JU Call for Proposals and Actions except where specifically derogated

Minimum conditions

Only RIA: At least 3 independent legal entities established in a different Member State or Associated Country

IMPORTANT! 1 legal entity should be established in a Member State

- Page limit: 20 pages for Short Proposal
- Contacts/discussions about a given topic between potential applicant consortia and members of the pre-identified industry consortium are prohibited throughout the procedure until the results of the first stage evaluation.
- First ranked applicant consortium will be invited to prepare and submit a 'full proposal (FP)' for the stage 2 evaluation together with the 'pre-identified industry consortium'.



Points to remember



Read all the callrelevant material: www.ihi.europa.eu



Begin forming your consortium early. Read the topic text. Check the IHI website and F&TP.



Ensure that all information is explicitly described in order to allow the expert evaluators to assess



Use the proposal structure / template



Coordinator must be financially viable – check in advance



Contact the IHI Office (<u>NOT</u> industry topic writers)



Reference Documents

- ✓ IHI Specific documents
- SBA
- Strategic Research and Innovation Agenda (SRIA)

All call related documents will be available by the Call launch in IHI website and in the Funding and Tenders portal

- ✓ Horizon Europe Reference documents
- HE Main Work Programme 2023–2025 13. General Annexes
- HE Programme Guide
- HE Framework Programme 2021/695
- HE Specific Programme Decision 2021/764
- EU Financial Regulation 2018/1046
- Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
- EU Grants AGA Annotated Model Grant Agreement
- Funding & Tenders Portal Online Manual
- Funding & Tenders Portal Terms and Conditions
- Funding & Tenders Portal Privacy Statement
- General Model Grant Agreement MGA v1.2



Your contact point

At the IHI Programme Office

General queries: applicants@ihi.europa.eu



Do you want to be an expert-evaluator?



- IHI JU (and the whole EU research family) are always looking for new, competent experts in diverse fields
- Create or update your expert profile via https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/work-as-an-expert
- E-mail <u>experts@ihi.europa.eu</u> mentioning your expert profile number (format EX20XX1234567)

#IHICallDays

innovative health initiative

Calls 9 & 10



7 Jan 10:30 Call 10: Digital labelling

8 Jan 10:30 Financial aspects of call 9

9 Jan 14:30 Call 10: PFAS exposure, emissions & end-of-life management

14 Jan 10:30 Call 9: General information

15 Jan 10:30 Call 9: Rules & procedures

15 Jan 14:30 Call 10: Secondary use of data in the European Health Data Space

16 Jan 10:30 Call 10: Rules & procedures

Online event















Everything you need to know about IHI contributing partners

Register now

30.01.2025

Online Event

















Questions and answers

→ Use the Q&A function

